Ibogaine compounds have been studied as potential therapies for treating mental health.
President Donald Trump ordered the Food and Drug Administration to expedite and prioritize reviews of research on the use of psychedelic drugs as medical therapies for mental health conditions.
“Policymakers and the medical field have long struggled to address the burden of suicide and serious mental illness rates in America,” President Trump’s order stated. “Critically, veterans often suffer in greater measure from this tragedy. For over 20 years, there have been more than 6,000 veteran suicides per year, and the current veteran suicide rate is more than twice as much as the non-veteran adult population.“
The president continued, “Despite massive Federal investment into researching potential advancements in mental health care and treatment, our medical research system has yet to produce approved therapies that promote enduring improvements in the mental health condition of these most complex patients. Innovative methods are needed to find long-term solutions for these Americans beyond existing prescription medications.”
“Psychedelic drugs, including ibogaine compounds, show potential in clinical studies to address serious mental illnesses for patients whose conditions persist after completing standard therapy. Indeed, the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to specific psychedelic drugs, and there are numerous products currently in the clinical trial pipeline for review of safety and efficacy,” President Trump explained. “It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America.”
As the Lord Leads, Pray with Us…
- For Commissioner Makary and FDA officials as they expedite the review of research on the use of psychedelics for mental health.
- For President Trump to be led by the Lord as he issues orders and sets domestic policy.
Sources: Time, The White House,
